The pulmoprotective effects of pirfenidone against paraquat-induced pulmonary toxicity: a systematic review
Abstract Objectives This systematic review aims to assess the pulmoprotective impacts of pirfenidone against paraquat-induced pulmonary toxicity, focusing on pirfenidone efficacy in mitigating pulmonary fibrosis and improving of pulmonary function. Methods A comprehensive literature search was perfo...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-06-01
|
| Series: | The Egyptian Journal of Bronchology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43168-025-00413-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Objectives This systematic review aims to assess the pulmoprotective impacts of pirfenidone against paraquat-induced pulmonary toxicity, focusing on pirfenidone efficacy in mitigating pulmonary fibrosis and improving of pulmonary function. Methods A comprehensive literature search was performed in several databases, including Web of Science, Scopus, and PubMed, to detect of studies investigated the effects of pirfenidone on paraquat-induced lung damage in animal models and humans. Inclusion criteria encompassed studies that reported on the therapeutic outcomes of pirfenidone, including its impact on lung fibrosis, pulmonary function, and oxidative stress biomarkers. Data were extracted and analyzed to assess the overall effectiveness of pirfenidone in these contexts. Results The review identified several studies demonstrated that pirfenidone significantly reduces lung fibrosis and enhances pulmonary function in rat models subjected to paraquat exposure. Key findings included a marked improvement in arterial blood gas parameters and a reduction in the amount of reactive oxygen species (ROS) associated with oxidative stress. Moreover, the combination therapy of pirfenidone with other medications such as prednisolone was found to further amplify therapeutic effects, suggesting a synergistic relationship that warrants further exploration. Conclusion Pirfenidone, particularly in inhaled formulation, exhibits promising pulmoprotective impacts against paraquat-induced pulmonary toxicity, offering a probably therapeutic approach for managing paraquat-related lung injury. While the current evidence supports its efficacy in pulmonary toxicity. Further studies are imperative to fully elucidate the mechanisms of action and improvement treatment protocols for clinical applications of pirfenidone in different pulmonary toxicity. Trial registration PROSPERO 1054188. |
|---|---|
| ISSN: | 2314-8551 |